Loading...
XOSLGENT
Market cap54mUSD
Dec 23, Last price  
40.20NOK
1D
3.08%
1Q
-12.61%
Jan 2017
-24.15%
IPO
43.57%
Name

Gentian Diagnostics ASA

Chart & Performance

D1W1MN
XOSL:GENT chart
P/E
—
P/S
4.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
24.19%
Revenues
136m
+34.00%
22,893,74224,554,41625,586,95430,896,88734,988,95946,108,22047,952,00068,369,00083,122,000101,636,000136,193,000
Net income
-11m
L-55.64%
873,987-2,908,559-3,222,155-8,926,987-15,169,906-19,798,354-39,857,000-17,114,000-24,794,000-24,001,000-10,648,000
CFO
15m
P
2,433,754-1,950,715-4,626,008-7,901,630-18,632,886-10,896,653-21,483,000-7,661,000-27,053,000-13,952,00015,458,000

Profile

Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. The company was incorporated in 2001 and is headquartered in Moss, Norway.
URL
https://www.gentian.com/
IPO date
Dec 14, 2016
Employees
55
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
136,193
34.00%
101,636
22.27%
83,122
21.58%
Cost of revenue
68,852
79,716
71,691
Unusual Expense (Income)
NOPBT
67,341
21,920
11,431
NOPBT Margin
49.45%
21.57%
13.75%
Operating Taxes
282
383
5,169
Tax Rate
0.42%
1.75%
45.22%
NOPAT
67,059
21,537
6,262
Net income
(10,648)
-55.64%
(24,001)
-3.20%
(24,794)
44.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
570
BB yield
-0.05%
Debt
Debt current
4,043
3,699
4,114
Long-term debt
22,055
26,947
33,054
Deferred revenue
Other long-term liabilities
Net debt
(61,645)
(50,953)
(77,768)
Cash flow
Cash from operating activities
15,458
(13,952)
(27,053)
CAPEX
(955)
(14,666)
(12,815)
Cash from investing activities
(4,877)
(14,666)
(12,815)
Cash from financing activities
(4,598)
(4,325)
(3,121)
FCF
72,705
13,872
(3,888)
Balance
Cash
87,642
81,599
114,936
Long term investments
101
Excess cash
80,933
76,517
110,780
Stockholders' equity
(165,507)
(154,935)
(119,044)
Invested Capital
325,192
319,463
308,796
ROIC
20.80%
6.86%
1.99%
ROCE
42.15%
13.32%
6.02%
EV
Common stock shares outstanding
15,422
15,422
15,415
Price
41.50
1.22%
41.00
-43.06%
72.00
32.11%
Market cap
640,013
1.22%
632,302
-43.03%
1,109,880
32.14%
EV
578,368
581,860
1,032,112
EBITDA
76,907
32,163
18,782
EV/EBITDA
7.52
18.09
54.95
Interest
871
1,255
1,454
Interest/NOPBT
1.29%
5.73%
12.72%